{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:51:42Z","timestamp":1787014302123,"version":"build-2736575974"},"reference-count":19,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the real\u2010world effectiveness of ubrogepant by evaluating self\u2010reported satisfaction with pain relief, ability to think clearly, and return to normal function in individuals who had used ubrogepant to treat a migraine episode within the preceding 14\u2009days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ubrogepant is an oral calcitonin gene\u2013related peptide receptor antagonist approved for the acute treatment of migraine in adults. Few studies have evaluated the real\u2010world effectiveness of ubrogepant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The UNIVERSE study was an observational, cross\u2010sectional survey conducted between February 2021 and April 2021 in US adult Migraine Buddy application (app) users currently treated with ubrogepant. Individuals who were 18\u2009years of age or older and reported at least one dose of ubrogepant in the previous 14\u2009days completed a 30\u2010question survey in the app. The survey assessed respondent demographics, migraine history, acute treatment patterns, and treatment satisfaction with ubrogepant. Respondents also reported prior acute medication use and reasons for switching to ubrogepant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 1303 ubrogepant users contacted, 302 (23.2%; 50\u2009mg, 120 participants; 100\u2009mg, 182 participants) were included in this study. The mean (standard deviation) age was 41.9 (11.2) years, and 90.1% (272\/302) were female. Satisfaction with migraine relief at 2, 4, and 24\u2009h post\u2010dose was reported by 75.8% (229\/302), 83.4% (252\/302), and 78.5% (237\/302) of participants, respectively. Satisfaction with the ability to think clearly after taking ubrogepant was reported by 85.1% (257\/302) of participants, and 83.8% (253\/302) were satisfied with their ability to return to normal function. Furthermore, 90.7% (274\/302) of participants reported that they were likely to continue using ubrogepant to treat their migraine. Most participants (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009264 [87%]) reported switching to ubrogepant due to inadequate treatment response with their previous treatment. In this subgroup, comparable outcomes were observed with respect to satisfaction with migraine relief, ability to think clearly, and return to normal function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ubrogepant demonstrated real\u2010world effectiveness in the acute treatment of migraine, as evidenced by high levels of treatment satisfaction and a strong indication of their intent to continue using the medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14839","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T07:56:16Z","timestamp":1727337376000},"page":"1244-1252","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ubrogepant users' real\u2010world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study"],"prefix":"10.1111","volume":"64","author":[{"given":"Anand R.","family":"Shewale","sequence":"first","affiliation":[{"name":"AbbVie  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Poh","sequence":"additional","affiliation":[{"name":"Healint Pte Ltd  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Reed","sequence":"additional","affiliation":[{"name":"Vedanta Research  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjie","family":"Liu","sequence":"additional","affiliation":[{"name":"Genesis Research  Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Cadiou","sequence":"additional","affiliation":[{"name":"Healint Pte Ltd  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ezzati","sequence":"additional","affiliation":[{"name":"Department of Neurology University of California  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Burslem","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaji","family":"Manthena","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-2897","authenticated-orcid":false,"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"The Saul R. Korey Department of Neurology Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra010917"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12499"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.12.020"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/2150132720963680"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905307"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13642"},{"key":"e_1_2_13_10_1","volume-title":"Ubrelvy [package insert]","year":"2023"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01110-9"},{"issue":"2","key":"e_1_2_13_14_1","first-page":"61","article-title":"Triptan use and discontinuation in a representative sample of persons with migraine: results from Migraine in America Symptoms and Treatments (MAST) study","volume":"58","author":"Alam A","year":"2018","journal-title":"Headache"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12198"},{"key":"e_1_2_13_16_1","article-title":"Analysis of treatment change of acute prescription migraine medications using real\u2010world evidence [abstract P91]","volume":"59","author":"Lipton RB","year":"2019","journal-title":"Headache"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13766"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.02050.x"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009324"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14018"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:55:05Z","timestamp":1762084505000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/head.14839"],"URL":"https:\/\/doi.org\/10.1111\/head.14839","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"assertion":[{"value":"2024-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}